HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kubota, K. Articles by Sole, M. J. Search for Related Content PubMed PubMed Citation Articles by Kubota, K. Articles by Sole, M. J.

Detection of Cardiomyopathy in an Animal Model Using Quantitative Autoradiography

Brookhaven National Laboratory, Upton, New York
State University of New York at Stony Brook, Stony Brook, New York
Oak Ridge National Laboratory, Oak Ridge, Tennessee
Toronto General Hospital, Toronto, Ontario

Correspondence: For reprints contact: P. Som, DVM, Medical Department, Brookhaven National Laboratory, Upton, NY 11973.

ABSTRACT

A fatty acid analog (15-p-iodophenyl)-3,3 dimethyl-pentadecanoic acid (DMIPP) was studied in cardiomyopathic (CM) and normal age-matched Syrian hamsters. Dual tracer quantitative wholebody autoradiography (QARG) with DMIPP and 2-[¹⁴C(U)]-2-deoxy-2-fluoro-D-glucose (FDG) or with FDG and ²⁰¹Tl enabled comparison of the uptake of a fatty acid and a glucose analog with the blood flow. These comparisons were carried out at the onset and mid-stage of the disease before congestive failure developed. Groups of CM and normal animals were treated with verapamil from the age of 26 days, before the onset of the disease for 41 days. In CM hearts, areas of decreased DMIPP uptake were seen. These areas were much larger than the decrease in uptake of FDG or ²⁰¹Tl. In early CM only minimal changes in FDG or ²⁰¹Tl uptake were observed as compared to controls. Treatment of CM-prone animals with verapamil prevented any changes in DMIPP, FDG, or ²⁰¹Tl uptake. DMIPP seems to be a more sensitive indicator of early cardiomyopathic changes as compared to ²⁰¹Tl or FDG. The trial of DMIPP and SPECT in the diagnosis of human disease, as well as for monitoring the effects of drugs which may prevent it seems to be warranted.

This article has been cited by other articles:

				H. Masuzaki, H. Jingami, N. Matsuoka, O. Nakagawa, Y. Ogawa, M. Mizuno, Y. Yoshimasa, T. Yamamoto, and K. Nakao Regulation of Very-Low-Density Lipoprotein Receptor in Hypertrophic Rat Heart Circ. Res., January 1, 1996; 78(1): 8 - 14. [Abstract] [Full Text]